Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Red5Lukeon Sep 27, 2018 9:28am
95 Views
Post# 28699696

RE:Talk 25th Sept. 2018 with Sirona Biochem

RE:Talk 25th Sept. 2018 with Sirona BiochemGreat interview with Howard - he seemed to have a cat that swallowed the canary smile on his face during the interview which bodes well for the future in my opinion.  The whole interview seemed very positive and Howard specially seemed upbeat and in a good place.   

My take-aways: 

TFC-1067 : Sounds like they have a near term partner in NA with them nearing the end of their due dilgence.  Other irons in the fire specifically in China and are looking at other Asian market partners too.  This translates into an even more profitable compound as they may have 2-3 or more partners at the end of the day paying upfront/milestone payments.  

All Other Compounds (minus TFC-039)  Seem to be in holding pattern until $ was in hand from TFC-1067.    

Attila:  Interviewer mentioned how Attila had built up expectations and you could see Howards face react negatively just at the mention of his name.  But he then mentioned how they now had formualted product sitting in front of them and that just added more value to the product line. 

Financing:  They want to keep dilution to minimum and are looking at a "strategic" partner for the financing - one that would add value or interest to the company.  Would be good to see a Bloom Burton or somebody/group of that level come on board via a financing. 
Bullboard Posts